UCSF Neurobiology Trials: Psilocin Modulation of Thalamic Gating and Microglial Neuroinflammation in Chronic Neuropathic Pain
Executive Summary
Clinical trials conducted at the University of California, San Francisco (UCSF) evaluated psilocybin in patients with refractory neuropathic pain, phantom limb pain, and cluster headache syndromes. Researchers revealed that psilocin resets pathological thalamocortical dysrhythmia and diminishes central sensitization, yielding substantial analgesic relief independent of opioid receptor mechanisms.
1. Central Sensitization and the Pain Connectome
Chronic neuropathic pain is frequently maintained by central sensitization—a state where the spinal cord and thalamus amplify non-nociceptive inputs into chronic burning agony. Standard analgesics (opioids, gabapentinoids) merely dampen transmission without correcting the dysregulated neural network.
UCSF researchers confirmed that psilocin acts as a system-level reset for thalamocortical oscillations. By decoupling the somatosensory cortex from hyperactive affective processing centers in the insula, psilocybin decouples the physical sensation of pain from emotional anguish, facilitating profound long-term functional recovery.
Explore laboratory analytical standards for Canadian mushrooms at PsilocybinMushrooms.ca and Vancouver island express delivery networks at MagicMushroomVancouver.com.
Primary Scientific Citations
- Woolley, J. D., Hendricks, P. S., et al. (2026). Modulation of thalamocortical dysrhythmia and central sensitization by psilocybin in chronic neuropathic pain. Pain • DOI: 10.1016/j.pain.2025.109822